Short answer
Verastem, Inc. (VSTM) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Updated corporate presentation posted November 5, 2026.
Verastem, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation posted November 5, 2026
- Exhibit 99.1 contains the presentation, potentially including updated business and investor information
Item EX-99.1 · Exhibit EX-99.1
- Corporate presentation outlines Verastem’s commercial and development strategy in RAS/MAPK-driven cancers
- AVMAPKI FAKZYNJA CO-PACK Q3 net product revenue $24M, with demand steady after Q2 growth
- Blister Pack NDA received FDA Priority Review, with PDUFA decision expected February 7, 2027
- RAMP 301 Phase 3 topline primary-endpoint readout expected mid-2027, supporting potential expansion beyond KRAS-mutant LGSOC
- VS-7375 KRAS G12D program enrolled 190+ patients, with additional efficacy updates expected across pancreatic, colorectal and lung cancer cohorts in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Verastem, Inc. 8-K filings
Get the next VSTM 8-K as it lands
Follow VSTM for push alerts, or ask the research agent what this filing means.